Lung Cancer in Women: Differences in Epidemiology, Biology, Histology, and Treatment Outcomes

 

 Buy Article Permissions and Reprints

Abstract

Lung cancer is a major health problem for both men and women, not only because of the high incidence rate but, more alarming, the high mortality rate. The prevalence of lung cancer in women has been increasing worldwide. In the United States, lung cancer is currently the leading cause of cancer death in women, and this may well be the case in European countries in just a few years. The most important risk factors for the development of lung cancer in both men and women is cigarette smoking. Smoking among women has increased significantly since the 1960s, and, unfortunately, the risk of death from cigarette smoking continues to increase among women. Although epidemiological data remain controversial regarding the increased risk of lung cancer from tobacco exposure in women, there is little controversy surrounding the fact that the biology of lung cancer differs between the sexes. This paper summarizes the explanations for the sex differences in lung cancer, including differences in molecular abnormalities, growth factor receptors, hormonal influences, cytochrome P-450 enzymes, and DNA repair capacity, as well as differences in the histology of lung cancer and treatment outcomes in women.

• References

• 1 Giovino GA. Epidemiology of tobacco use in the United States. Oncogene 2002; 21 (48) 7326-7340
  CrossrefPubMedGoogle Scholar
• 2 Fiore MC, Novotny TE, Pierce JP, Hatziandreu EJ, Patel KM, Davis RM. Trends in cigarette smoking in the United States. The changing influence of gender and race. JAMA 1989; 261 (1) 49-55
  CrossrefPubMedGoogle Scholar
• 3 World Health Organization (WHO). Women and Health: Today's Evidence, Tomorrow's Agenda. Geneva, Switzerland: World Health Organization; 2009
  Google Scholar
• 4 Mackay J, Eriksen MP, Shafey O. The Tobacco Atlas. 2nd ed. Atlanta, GA: American Cancer Society; 2006
  Google Scholar
• 5 Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults in the United States 2011. MMWR Morb Mortal Wkly Rep 2012; 61 (44) 889-894
  PubMedGoogle Scholar
• 6 Eaton DK, Kann L, Kinchen S , et al; Centers for Disease Control and Prevention (CDC). Youth risk behavior surveillance—United States, 2011. MMWR Surveill Summ 2012; 61 (4) 1-162
  PubMedGoogle Scholar
• 7 Cigarettes smoking: Slight fall in smoking prevalence [database on the Internet]. www.statistics.gov.uk/hub/health-social-case/health-of-the-population United Kingdom Office of National Statistics, 2006 [cited April 15, 2013]
  PubMedGoogle Scholar
• 8 Center for Disease Control and Prevention (CDC). www.who.int/tabacco/surveillance/2009-gats-report-phillipines Global adult tobacco survey: Philippines Data; 2009. [cited April 15, 2013]
  PubMed
• 9 World Health Organization. www.who.int/tabacco/wntd/2010/announcement World No Tobacco Day 2010: Theme: Gender and tobacco with an emphasis on marketing to women. Geneva, Switzerland: World Health Organization; 2009. [cited May 2 2012]
  Google Scholar
• 10 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63 (1) 11-30
  CrossrefPubMedGoogle Scholar
• 11 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J , et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49 (6) 1374-1403
  CrossrefPubMedGoogle Scholar
• 12 Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol 2013; 24 (3) 792-800
  CrossrefPubMedGoogle Scholar
• 13 Thun MJ, Carter BD, Feskanich D , et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013; 368 (4) 351-364
  CrossrefPubMedGoogle Scholar
• 14 Pirie K, Peto R, Reeves GK, Green J, Beral V ; Million Women Study Collaborators. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet 2013; 381 (9861) 133-141
  CrossrefPubMedGoogle Scholar
• 15 Lubin JH, Blot WJ. Assessment of lung cancer risk factors by histologic category. J Natl Cancer Inst 1984; 73 (2) 383-389
  PubMedGoogle Scholar
• 16 Brownson RC, Chang JC, Davis JR. Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology 1992; 3 (1) 61-64
  CrossrefPubMedGoogle Scholar
• 17 Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 1993; 138 (5) 281-293
  CrossrefPubMedGoogle Scholar
• 18 Schoenberg JB, Wilcox HB, Mason TJ, Bill J, Stemhagen A. Variation in smoking-related lung cancer risk among New Jersey women. Am J Epidemiol 1989; 130 (4) 688-695
  PubMedGoogle Scholar
• 19 Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer 1993; 54 (1) 44-48
  CrossrefPubMedGoogle Scholar
• 20 Harris RE, Zang EA, Anderson JI, Wynder EL. Race and sex differences in lung cancer risk associated with cigarette smoking. Int J Epidemiol 1993; 22 (4) 592-599
  CrossrefPubMedGoogle Scholar
• 21 Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996; 88 (3-4) 183-192
  CrossrefPubMedGoogle Scholar
• 22 McDuffie HH, Klaassen DJ, Dosman JA. Female-male differences in patients with primary lung cancer. Cancer 1987; 59 (10) 1825-1830
  CrossrefPubMedGoogle Scholar
• 23 Prescott E, Osler M, Hein HO , et al; The Copenhagen Center for Prospective Population Studies. Gender and smoking-related risk of lung cancer. Epidemiology 1998; 9 (1) 79-83
  CrossrefPubMedGoogle Scholar
• 24 Kreuzer M, Boffetta P, Whitley E , et al. Gender differences in lung cancer risk by smoking: a multicentre case-control study in Germany and Italy. Br J Cancer 2000; 82 (1) 227-233
  CrossrefPubMedGoogle Scholar
• 25 Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993; 85 (6) 457-464
  CrossrefPubMedGoogle Scholar
• 26 Bach PB, Kattan MW, Thornquist MD , et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003; 95 (6) 470-478
  CrossrefPubMedGoogle Scholar
• 27 Bain C, Feskanich D, Speizer FE , et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 2004; 96 (11) 826-834
  CrossrefPubMedGoogle Scholar
• 28 De Matteis S, Consonni D, Pesatori AC , et al. Are women who smoke at higher risk for lung cancer than men who smoke?. Am J Epidemiol 2013; 177 (7) 601-612
  CrossrefPubMedGoogle Scholar
• 29 Thun MJ, Hannan LM, Adams-Campbell LL , et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 2008; 5 (9) e185
  CrossrefPubMedGoogle Scholar
• 30 Wakelee HA, Chang ET, Gomez SL , et al. Lung cancer incidence in never smokers. J Clin Oncol 2007; 25 (5) 472-478
  CrossrefPubMedGoogle Scholar
• 31 Chiba I, Takahashi T, Nau MM , et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 1990; 5 (10) 1603-1610
  PubMedGoogle Scholar
• 32 Takahashi T, Takahashi T, Suzuki H , et al. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 1991; 6 (10) 1775-1778
  PubMedGoogle Scholar
• 33 Kure EH, Ryberg D, Hewer A , et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis 1996; 17 (10) 2201-2205
  CrossrefPubMedGoogle Scholar
• 34 Guinee Jr DG, Travis WD, Trivers GE , et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis 1995; 16 (5) 993-1002
  CrossrefPubMedGoogle Scholar
• 35 Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003; 21 (3) 229-239
  CrossrefPubMedGoogle Scholar
• 36 Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9 (2) 95-107
  CrossrefPubMedGoogle Scholar
• 37 Ahrendt SA, Decker PA, Alawi EA , et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001; 92 (6) 1525-1530
  CrossrefPubMedGoogle Scholar
• 38 Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999; 91 (23) 2032-2038
  CrossrefPubMedGoogle Scholar
• 39 Aaronson SA. Growth factors and cancer. Science 1991; 254 (5035) 1146-1153
  CrossrefPubMedGoogle Scholar
• 40 Siegfried JM, DeMichele MA, Hunt JD, Davis AG, Vohra KP, Pilewski JM. Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells. Association with prolonged tobacco exposure and responsiveness to bombesin-like peptides. Am J Respir Crit Care Med 1997; 156 (2 Pt 1) 358-366
  CrossrefPubMedGoogle Scholar
• 41 Ohki-Hamazaki H, Iwabuchi M, Maekawa F. Development and function of bombesin-like peptides and their receptors. Int J Dev Biol 2005; 49 (2-3) 293-300
  CrossrefPubMedGoogle Scholar
• 42 Cuttitta F, Carney DN, Mulshine J , et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316 (6031) 823-826
  CrossrefPubMedGoogle Scholar
• 43 Leyton J, Garcia-Marin LJ, Tapia JA, Jensen RT, Moody TW. Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in non-small cell lung cancer cells. Cancer Lett 2001; 162 (1) 87-95
  CrossrefPubMedGoogle Scholar
• 44 Shriver SP, Bourdeau HA, Gubish CT , et al. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst 2000; 92 (1) 24-33
  CrossrefPubMedGoogle Scholar
• 45 Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004; 10 (12 Pt 2) 4227s-4232s
  CrossrefPubMedGoogle Scholar
• 46 Paez JG, Jänne PA, Lee JC , et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304 (5676) 1497-1500
  CrossrefPubMedGoogle Scholar
• 47 Rosell R, Moran T, Queralt C , et al; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361 (10) 958-967
  CrossrefPubMedGoogle Scholar
• 48 Pellegrini C, Falleni M, Marchetti A , et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 2003; 9 (10 Pt 1) 3645-3652
  PubMedGoogle Scholar
• 49 Hirsch F, Veve R, Varella-Garcia M. Evaluation of Her2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization [abstract]. Proc Am Soc Clin Oncol 2000; 19: 486a
  PubMedGoogle Scholar
• 50 Hsieh CC, Chow KC, Fahn HJ , et al. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg 1998; 66 (4) 1159-1163 , discussion 1163–1164
  CrossrefPubMedGoogle Scholar
• 51 Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993; 53 (13) 2994-2999
  PubMedGoogle Scholar
• 52 Gonzalez FJ, Crespi CL, Gelboin HV. DNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutat Res 1991; 247 (1) 113-127
  CrossrefPubMedGoogle Scholar
• 53 Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91 (14) 1194-1210
  CrossrefPubMedGoogle Scholar
• 54 Seidegård J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis 1990; 11 (1) 33-36
  CrossrefPubMedGoogle Scholar
• 55 Mollerup S, Ryberg D, Hewer A, Phillips DH, Haugen A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 1999; 59 (14) 3317-3320
  PubMedGoogle Scholar
• 56 Spitz MR, Wei Q, Dong Q, Amos CI, Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev 2003; 12 (8) 689-698
  PubMedGoogle Scholar
• 57 Kriek E, Rojas M, Alexandrov K, Bartsch H. Polycyclic aromatic hydrocarbon-DNA adducts in humans: relevance as biomarkers for exposure and cancer risk. Mutat Res 1998; 400 (1-2) 215-231
  PubMedGoogle Scholar
• 58 Peluso M, Munnia A, Hoek G , et al. DNA adducts and lung cancer risk: a prospective study. Cancer Res 2005; 65 (17) 8042-8048
  PubMedGoogle Scholar
• 59 Gorlova OY, Weng SF, Zhang Y, Amos CI, Spitz MR, Wei Q. DNA repair capacity and lung cancer risk in never smokers. Cancer Epidemiol Biomarkers Prev 2008; 17 (6) 1322-1328
  CrossrefPubMedGoogle Scholar
• 60 Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994; 54 (22) 5801-5803
  PubMedGoogle Scholar
• 61 Wei Q, Cheng L, Amos CI , et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000; 92 (21) 1764-1772
  CrossrefPubMedGoogle Scholar
• 62 Cheng YW, Hsieh LL, Lin PP , et al. Gender difference in DNA adduct levels among nonsmoking lung cancer patients. Environ Mol Mutagen 2001; 37 (4) 304-310
  CrossrefPubMedGoogle Scholar
• 63 Stabile LP, Davis AL, Gubish CT , et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor . α and β and show biological responses to estrogen. Cancer Res 2002; 62 (7) 2141-2150
  PubMedGoogle Scholar
• 64 Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996; 36: 203-232
  CrossrefPubMedGoogle Scholar
• 65 Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol 2001; 21 (1) 6-12
  CrossrefPubMedGoogle Scholar
• 66 Gao YT, Blot WJ, Zheng W , et al. Lung cancer among Chinese women. Int J Cancer 1987; 40 (5) 604-609
  CrossrefPubMedGoogle Scholar
• 67 Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994; 86 (11) 869-870
  CrossrefPubMedGoogle Scholar
• 68 Weiss JM, Lacey Jr JV, Shu XO , et al. Menstrual and reproductive factors in association with lung cancer in female lifetime nonsmokers. Am J Epidemiol 2008; 168 (11) 1319-1325
  CrossrefPubMedGoogle Scholar
• 69 Baik CS, Strauss GM, Speizer FE, Feskanich D. Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev 2010; 19 (10) 2525-2533
  CrossrefPubMedGoogle Scholar
• 70 Brinton LA, Gierach GL, Andaya A , et al. Reproductive and hormonal factors and lung cancer risk in the NIH-AARP Diet and Health Study cohort. Cancer Epidemiol Biomarkers Prev 2011; 20 (5) 900-911
  CrossrefPubMedGoogle Scholar
• 71 Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989; 44 (5) 833-839
  CrossrefPubMedGoogle Scholar
• 72 Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 2004; 10 (1 Pt 1) 113-123
  CrossrefPubMedGoogle Scholar
• 73 Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of lung cancer-Systematic review and meta-analysis. Maturitas 2010; 65 (3) 198-204
  CrossrefPubMedGoogle Scholar
• 74 Chlebowski RT, Schwartz AG, Wakelee H , et al; Women's Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009; 374 (9697) 1243-1251
  CrossrefPubMedGoogle Scholar
• 75 Hulley S, Furberg C, Barrett-Connor E , et al; HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288 (1) 58-66
  CrossrefPubMedGoogle Scholar
• 76 Pesatori AC, Carugno M, Consonni D , et al. Reproductive and hormonal factors and the risk of lung cancer: the EAGLE study. Int J Cancer 2013; 132 (11) 2630-2639
  CrossrefPubMedGoogle Scholar
• 77 Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003; 17 (3) 309-317
  CrossrefPubMedGoogle Scholar
• 78 Garon EB, Pietras RJ, Finn RS , et al. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol 2013; 8 (3) 270-278
  CrossrefPubMedGoogle Scholar
• 79 Siegfried JM, Gubish CT, Rothstein ME, Henry C, Stabile LP. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J Thorac Oncol 2012; 7 (3) 485-495
  CrossrefPubMedGoogle Scholar
• 80 Shen H, Yuan Y, Sun J, Gao W, Shu YQ. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother 2010; 64 (2) 88-92
  CrossrefPubMedGoogle Scholar
• 81 Chang YH, Huang HD, Shiau MY , et al. The correlation of IL-6 and MCL-6 expression in human papilloma virus 16/18 infected lung cancer. Proc Int Assoc Stud Lung Cancer 2003; 41 (Suppl. 02) S119
  PubMedGoogle Scholar
• 82 Hennig EM, Suo Z, Karlsen F, Holm R, Thoresen S, Nesland JM. HPV positive bronchopulmonary carcinomas in women with previous high-grade cervical intraepithelial neoplasia (CIN III). Acta Oncol 1999; 38 (5) 639-647
  CrossrefPubMedGoogle Scholar
• 83 Cheng YW, Chiou HL, Sheu GT , et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001; 61 (7) 2799-2803
  PubMedGoogle Scholar
• 84 Gorgoulis VG, Zacharatos P, Kotsinas A , et al. Human papilloma virus (HPV) is possibly involved in laryngeal but not in lung carcinogenesis. Hum Pathol 1999; 30 (3) 274-283
  CrossrefPubMedGoogle Scholar
• 85 Welt A, Hummel M, Niedobitek G, Stein H. Human papillomavirus infection is not associated with bronchial carcinoma: evaluation by in situ hybridization and the polymerase chain reaction. J Pathol 1997; 181 (3) 276-280
  CrossrefPubMedGoogle Scholar
• 86 Greenberg ER, Korson R, Baker J, Barrett J, Baron JA, Yates J. Incidence of lung cancer by cell type: a population-based study in New Hampshire and Vermont. J Natl Cancer Inst 1984; 72 (3) 599-603
  PubMedGoogle Scholar
• 87 Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, Heath Jr CW. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997; 89 (21) 1580-1586
  CrossrefPubMedGoogle Scholar
• 88 Stellman SD, Muscat JE, Thompson S, Hoffmann D, Wynder EL. Risk of squamous cell carcinoma and adenocarcinoma of the lung in relation to lifetime filter cigarette smoking. Cancer 1997; 80 (3) 382-388
  CrossrefPubMedGoogle Scholar
• 89 Barkley JE, Green MR. Bronchioloalveolar carcinoma. J Clin Oncol 1996; 14 (8) 2377-2386
  PubMedGoogle Scholar
• 90 Albertine KH, Steiner RM, Radack DM , et al. Analysis of cell type and radiographic presentation as predictors of the clinical course of patients with bronchioalveolar cell carcinoma. Chest 1998; 113 (4) 997-1006
  CrossrefPubMedGoogle Scholar
• 91 Travis WD, Brambilla E, Noguchi M , et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6 (2) 244-285
  CrossrefPubMedGoogle Scholar
• 92 Alterkrouse SF, Kosary CL, Krapcho M , et al. SEER Cancer Statistics Review 1975–2010. National Cancer Institute. http://seer.cancer.gov . Posted SEER web site April 2013
  PubMedGoogle Scholar
• 93 Schoenberg JB, Wilcox HB, Mason TJ, Bill J, Stemhagen A. Variation in smoking-related lung cancer risk among New Jersey women. Am J Epidemiol 1989; 130 (4) 688-695
  PubMedGoogle Scholar
• 94 Ramalingam S, Pawlish K, Gadgeel S, Demers R, Kalemkerian GP. Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol 1998; 16 (2) 651-657
  PubMedGoogle Scholar
• 95 Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest 2005; 127 (3) 768-777
  CrossrefPubMedGoogle Scholar
• 96 Radzikowska E, Głaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002; 13 (7) 1087-1093
  CrossrefPubMedGoogle Scholar
• 97 Asamura H, Goya T, Koshiishi Y , et al; Japanese Joint Committee of Lung Cancer Registry. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008; 3 (1) 46-52
  CrossrefPubMedGoogle Scholar
• 98 Mitsudomi T, Tateishi M, Oka T, Yano T, Ishida T, Sugimachi K. Longer survival after resection of non-small cell lung cancer in Japanese women. Ann Thorac Surg 1989; 48 (5) 639-642
  CrossrefPubMedGoogle Scholar
• 99 Minami H, Yoshimura M, Miyamoto Y, Matsuoka H, Tsubota N. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest 2000; 118 (6) 1603-1609
  CrossrefPubMedGoogle Scholar
• 100 Ferguson MK, Wang J, Hoffman PC , et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg 2000; 69 (1) 245-249 , discussion 249–250
  CrossrefPubMedGoogle Scholar
• 101 Cerfolio RJ, Bryant AS, Scott E , et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006; 130 (6) 1796-1802
  CrossrefPubMedGoogle Scholar
• 102 Movsas B, Bac K, Langer CJ , et al. The influence of gender, race, and/or marital status on survival in lung cancer patients: meta-analysis of radiation therapy oncology group (RTOG) trials. J Thorac Oncol 2010; 5 (5) 631-9
  PubMedGoogle Scholar
• 103 O'Connell JP, Kris MG, Gralla RJ , et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986; 4 (11) 1604-1614
  PubMedGoogle Scholar
• 104 Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8 (9) 1563-1574
  PubMedGoogle Scholar
• 105 Videtic GM, Reddy CA, Chao ST , et al. Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the Radiation Therapy Oncology Group recursive partitioning analysis classification. Int J Radiat Oncol Biol Phys 2009; 75 (4) 1141-1147
  CrossrefPubMedGoogle Scholar
• 106 Fukuoka M, Yano S, Giaccone G , et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21 (12) 2237-2246
  CrossrefPubMedGoogle Scholar
• 107 Kris MG, Natale RB, Herbst RS , et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290 (16) 2149-2158
  CrossrefPubMedGoogle Scholar
• 108 Shepherd FA, Rodrigues Pereira J, Ciuleanu T , et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353 (2) 123-132
  CrossrefPubMedGoogle Scholar
• 109 Lynch TJ, Bell DW, Sordella R , et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350 (21) 2129-2139
  CrossrefPubMedGoogle Scholar
• 110 Sekine I, Sumi M, Ito Y , et al. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy. Jpn J Clin Oncol 2009; 39 (11) 707-712
  CrossrefPubMedGoogle Scholar
• 111 Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2006; 24 (1) 59-63
  CrossrefPubMedGoogle Scholar
• 112 Chlebowski RT, Anderson GL, Manson JE , et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst 2010; 102 (18) 1413-1421
  CrossrefPubMedGoogle Scholar